Nazari-Jahantigh Maliheh, Egea Virginia, Schober Andreas, Weber Christian
Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany.
Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.
J Mol Cell Cardiol. 2015 Dec;89(Pt A):35-41. doi: 10.1016/j.yjmcc.2014.10.021. Epub 2014 Nov 8.
During the past decade, the crucial role of microRNAs (miRs) controlling tissue homeostasis and disease in the cardiovascular system has become widely recognized. By controlling the expression levels of their targets, several miRs have been shown to modulate the function of endothelial cells, vascular smooth muscle cells, and macrophages, thereby regulating the development and progression of atherosclerosis. For instance, miR-155 can exacerbate early stages of atherosclerosis by increasing the inflammatory activation and disturbing efficient lipid handling in macrophages. Conversely, miRs can exert atheroprotective roles, as has been established for the complementary miR-126 strand pair, which forms a dual system sustaining the endothelial proliferative reserve and promoting endothelial regeneration to counteract atherogenic effects of disturbed flow and hyperlipidemia. Under some conditions, miRs are released from cells and are transported by microvesicles, ribonucleoprotein complexes, and lipoproteins, being remarkably stable in circulation. Conferred by such delivery modules, miRs can regulate target mRNAs in recipient cells, representing a new tool for cell-cell communication in the context of atherosclerotic disease. Here, we will discuss novel aspects of miR-mediated regulatory mechanisms, namely the regulation by competing RNA targets, miRNA tandems, or complementary miR strand pairs, as well as their potential diagnostic and therapeutic value in atherosclerosis. This article is part of a Special Issue entitled 'Non-coding RNAs'.
在过去十年中,微小RNA(miR)在心血管系统中控制组织稳态和疾病方面的关键作用已得到广泛认可。通过控制其靶标的表达水平,已证明几种miR可调节内皮细胞、血管平滑肌细胞和巨噬细胞的功能,从而调节动脉粥样硬化的发展和进程。例如,miR-155可通过增加炎症激活和扰乱巨噬细胞中有效的脂质处理来加剧动脉粥样硬化的早期阶段。相反,miR可发挥抗动脉粥样硬化作用,如互补的miR-126链对所证实的那样,它形成了一个双重系统,维持内皮细胞增殖储备并促进内皮细胞再生,以抵消血流紊乱和高脂血症的致动脉粥样硬化作用。在某些情况下,miR从细胞中释放出来,并通过微泡、核糖核蛋白复合物和脂蛋白进行运输,在循环中非常稳定。通过这种传递模块,miR可以调节受体细胞中的靶mRNA,这代表了动脉粥样硬化疾病背景下细胞间通讯的一种新工具。在这里,我们将讨论miR介导的调节机制的新方面,即通过竞争性RNA靶标、miRNA串联体或互补miR链对进行的调节,以及它们在动脉粥样硬化中的潜在诊断和治疗价值。本文是名为“非编码RNA”的特刊的一部分。